MA22672A1 - Procede de production d'heteroarylamines inhibitrices d'acetylcholinesterase - Google Patents

Procede de production d'heteroarylamines inhibitrices d'acetylcholinesterase

Info

Publication number
MA22672A1
MA22672A1 MA22956A MA22956A MA22672A1 MA 22672 A1 MA22672 A1 MA 22672A1 MA 22956 A MA22956 A MA 22956A MA 22956 A MA22956 A MA 22956A MA 22672 A1 MA22672 A1 MA 22672A1
Authority
MA
Morocco
Prior art keywords
heteroarylamines
producing
acetylcholinesterase inhibitory
acetylcholinesterase
inhibitory
Prior art date
Application number
MA22956A
Other languages
English (en)
French (fr)
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of MA22672A1 publication Critical patent/MA22672A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)
MA22956A 1991-10-03 1992-10-02 Procede de production d'heteroarylamines inhibitrices d'acetylcholinesterase MA22672A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77128391A 1991-10-03 1991-10-03

Publications (1)

Publication Number Publication Date
MA22672A1 true MA22672A1 (fr) 1993-07-01

Family

ID=25091318

Family Applications (1)

Application Number Title Priority Date Filing Date
MA22956A MA22672A1 (fr) 1991-10-03 1992-10-02 Procede de production d'heteroarylamines inhibitrices d'acetylcholinesterase

Country Status (36)

Country Link
US (4) US5574046A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0606248B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2546785B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR0170458B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1035615C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP314A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE235490T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU667053B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG61727B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9206577A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2119647C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ290807B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69232976T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0606248T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG21481A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2193137T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI116939B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU225049B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL103274A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS1745B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA22672A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9205678A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO308533B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ244601A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA09895A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31290A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL171984B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT100917B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO112868B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2100357C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG52618A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW263504B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA41290C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY23484A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993007140A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA927589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU758802B2 (en) 1998-09-30 2003-03-27 Takeda Pharmaceutical Company Limited Drugs for improving vesical excretory strength
SE9902268D0 (sv) * 1999-06-16 1999-06-16 Astra Ab Pharmaceutically active compounds
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
CA2422717A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
EP1554271A1 (en) * 2002-10-15 2005-07-20 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
WO2005112908A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function
EP1600447A1 (en) * 2004-05-28 2005-11-30 Neuropharma S.A.U. Butyrylcholinesterase selective inhibitors
MXPA06014471A (es) 2004-06-09 2007-03-21 Glaxo Group Ltd Derivados de pirrolopiridina.
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
CN1808106B (zh) * 2005-01-21 2010-11-24 中国科学院上海药物研究所 一种用核磁共振筛选乙酰胆碱酯酶抑制剂的方法
AU2009282114B2 (en) 2008-08-12 2016-04-07 Zinfandel Pharmaceuticals, Inc. Method of identifying disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
JP6012468B2 (ja) 2009-10-02 2016-10-25 アヴェクシン エーエス 抗炎症性2−オキソチアゾールおよび2−オキソオキサゾール
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2012096873A1 (en) 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014118195A1 (en) 2013-01-29 2014-08-07 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN107141266B (zh) * 2017-06-28 2019-04-09 佳木斯大学附属第一医院 一种用于治疗阿尔茨海默病的杂环化合物及其制备方法
CN115466211B (zh) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 一种n-苯基喹啉-4-胺类化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068259B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1954-04-28 1959-11-05
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4122265A (en) * 1976-05-21 1978-10-24 Hoffmann-La Roche Inc. Derivatives of 3-phenylisoindole-1-carboxylic acid
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8615562D0 (en) * 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IT1226100B (it) * 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
US5064840A (en) * 1989-08-03 1991-11-12 Merrell Dow Pharmaceuticals Anti-psychotic piperidylbenzimidazole compounds
TW197442B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-02-08 1993-01-01 Pfizer
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
TW197435B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DE69330823T2 (de) * 1992-02-13 2002-05-02 Merrell Pharmaceuticals Inc., Cincinnati Thiacyclische piperidinylderivate
CA2092112A1 (en) * 1992-03-23 1993-09-24 Nobuyoshi Iwata Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use

Also Published As

Publication number Publication date
PT100917B (pt) 1999-07-30
US5574046A (en) 1996-11-12
KR0170458B1 (ko) 1999-02-18
PH31290A (en) 1998-07-06
WO1993007140A1 (en) 1993-04-15
PT100917A (pt) 1993-11-30
IL103274A (en) 1996-11-14
CZ78594A3 (en) 1995-07-12
IL103274A0 (en) 1993-02-21
SG52618A1 (en) 1998-09-28
HUT70544A (en) 1995-10-30
DE69232976D1 (de) 2003-04-30
UA41290C2 (uk) 2001-09-17
AU667053B2 (en) 1996-03-07
AP9200421A0 (en) 1992-10-31
MX9205678A (es) 1993-04-01
AU2519692A (en) 1993-05-03
EP0606248A1 (en) 1994-07-20
EG21481A (en) 2001-11-28
RO112868B1 (ro) 1998-01-30
AP314A (en) 1994-02-04
IS3919A (is) 1993-04-04
BG98689A (bg) 1995-03-31
TW263504B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-11-21
PL171984B1 (pl) 1997-07-31
CZ290807B6 (cs) 2002-10-16
FI941518A0 (fi) 1994-03-31
FI116939B (fi) 2006-04-13
CA2119647A1 (en) 1993-04-15
HU9400952D0 (en) 1994-06-28
ES2193137T3 (es) 2003-11-01
BR9206577A (pt) 1995-10-10
NO941179L (no) 1994-03-30
CN1035615C (zh) 1997-08-13
PL171669B1 (en) 1997-06-30
US6124321A (en) 2000-09-26
CA2119647C (en) 1998-08-04
PL171693B1 (pl) 1997-06-30
US20020049210A1 (en) 2002-04-25
NZ244601A (en) 1995-03-28
CN1071166A (zh) 1993-04-21
NO308533B1 (no) 2000-09-25
HU225049B1 (en) 2006-05-29
JPH06510788A (ja) 1994-12-01
FI941518L (fi) 1994-03-31
DE9290112U1 (de) 1994-06-01
OA09895A (en) 1995-09-15
NO941179D0 (no) 1994-03-30
ATE235490T1 (de) 2003-04-15
RU2100357C1 (ru) 1997-12-27
IS1745B (is) 2000-05-18
DE69232976T2 (de) 2003-10-02
DK0606248T3 (da) 2003-06-23
BG61727B1 (bg) 1998-04-30
JP2546785B2 (ja) 1996-10-23
US6303633B1 (en) 2001-10-16
EP0606248B1 (en) 2003-03-26
UY23484A1 (es) 1993-03-11
ZA927589B (en) 1994-04-05

Similar Documents

Publication Publication Date Title
MA22672A1 (fr) Procede de production d'heteroarylamines inhibitrices d'acetylcholinesterase
MA21610A1 (fr) Procede de production de composes triazoliques .
FR2634194B1 (fr) Procede de production d'alumines boehmitiques
FR2624865B1 (fr) Procede de production de polybutenes
FR2582294B1 (fr) Procede de production d'alumine-beta
BE878902A (fr) Procede de production d'alkylene-glycols
FR2671801B1 (fr) Procede de production de glycomacropeptides de kappa-caseine.
HU912005D0 (en) Process for the production of aminobenzodiazepines
FR2661913B1 (fr) Procede de production de polychloroprene.
HU913290D0 (en) Process for the production of cyuclodextrines
HU910151D0 (en) Process for the production of substituted 2-chloride-pyridines
MA23714A1 (fr) Procede de production de n-phosphonomethylglycine
MA22151A1 (fr) Procede de production d'azabenzimidazoles
FR2678625B1 (fr) Procede de production d'acetate de cellulose.
FR2676221B1 (fr) Procede de fabrication d'articles en vitroceramique decores.
FR2559490B1 (fr) Procede de production d'oligoglucosylfructosides tres purs
HU9200354D0 (en) Process for the production of 2-ethyl-4-/2'/-1h-1,2,3,4-tetrazole-5-yl/-biphenyl-4-yl/-metoxi/-kinoline-hydrocloride
FR2630105B1 (fr) Procede de fabrication des dialkyldisulfures inferieurs
FR2663941B1 (fr) Procede de production d'organosiloxanes.
FR2625194B1 (fr) Procede de production d'aldehydes aromatiques
FR2623511B1 (fr) Procede de production de polymeres d'organophosphazene
HU208490B (en) Process for producing aluminium-potassium-sulfate-containing ointment
FR2595714B1 (fr) Procede perfectionne de production d'interleukine-0
FR2696475B1 (fr) Procede de production de micro-algues.
HU913228D0 (en) Process for the production of 5-aroil-2,3-dihydro-1h-pyrrholyzine-1,1-dicarboxylates